V6M1 Stock Overview
A biopharmaceutical company, focuses on identification, development, and commercialization of novel, patent protected products for the treatment of rare metabolic, dermatological, and pulmonary diseases in Switzerland, Europe, North America, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Relief Therapeutics Holding SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 2.11 |
| 52 Week High | CHF 10.78 |
| 52 Week Low | CHF 2.11 |
| Beta | -14.36 |
| 11 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | -80.47% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -88.63% |
Recent News & Updates
Recent updates
Shareholder Returns
| V6M1 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | 0.8% | -1.3% |
| 1Y | -80.5% | -17.5% | 7.4% |
Return vs Industry: V6M1 underperformed the German Biotechs industry which returned -24.1% over the past year.
Return vs Market: V6M1 underperformed the German Market which returned 2.3% over the past year.
Price Volatility
| V6M1 volatility | |
|---|---|
| V6M1 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: V6M1 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine V6M1's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 69 | Michelle Lock | www.relieftherapeutics.com |
Relief Therapeutics Holding AG, a biopharmaceutical company, focuses on identification, development, and commercialization of novel, patent protected products for the treatment of metabolic, dermatological, and pulmonary rare diseases in Switzerland, Europe, North America, and internationally. The company offers SETOFILM/ONDISSOLVE for radiotherapy induced nausea and vomiting, and chemotherapy induced nausea and vomiting, as well as postoperative induced nausea and vomiting. It develops RLF-100, a synthetic form of vasoactive intestinal peptide (VIP) for the treatment of acute respiratory distress syndrome (ARDS) associated with COVID-19, nonCOVID-19-related ARDS, pulmonary sarcoidosis, checkpoint inhibitor-induced pneumonitis, and chronic berylliosis.
Relief Therapeutics Holding SA Fundamentals Summary
| V6M1 fundamental statistics | |
|---|---|
| Market cap | €21.04m |
| Earnings (TTM) | -€84.73m |
| Revenue (TTM) | €6.15m |
3.4x
P/S Ratio-0.2x
P/E RatioIs V6M1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| V6M1 income statement (TTM) | |
|---|---|
| Revenue | CHF 5.86m |
| Cost of Revenue | CHF 1.45m |
| Gross Profit | CHF 4.41m |
| Other Expenses | CHF 85.20m |
| Earnings | -CHF 80.79m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -6.44 |
| Gross Margin | 75.26% |
| Net Profit Margin | -1,378.18% |
| Debt/Equity Ratio | 1.8% |
How did V6M1 perform over the long term?
See historical performance and comparison